Today the company said its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study.
Tag Archive for: Xenon Pharmaceuticals
Neurocrine Biosciences on Thursday announced that two of its candidates—from separate partnerships with Xenon Pharmaceuticals and Takeda—failed their respective Phase II studies in focal onset seizures and major depressive disorder.
Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.